Sandoz launches MabThera, Enbrel biosimilars in the UK
Novartis group Sandoz has launched two new biosimilars across the UK potentially expanding access to biologic treatments for a range of inflammatory conditions and blood cancers.
Read More
Tag: etanercept
December CHMP decisions bring year’s total approvals to 81
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has backed seven new medicines for approval at its December meeting, bringing the total number recommended during the year to 81, dropping from 2015’s tally of 93.
Read More
Shire steps away from biosimilars
Shire has handed back rights to the two biosimilars it acquired through its recent purchase of Baxalta, retaining its focus on the development of drugs for rare diseases.
Read More
FDA green light for Sandoz’ Enbrel biosimilar
The US Food and Drug Administration has approved Sandoz’ biosimilar of Amgen’s blockbuster Enbrel.
Read More
FDA advisors back Sandoz’ Enbrel biosimilar
Sandoz’ biosimilar of Amgen’s blockbuster Enbrel has taken a big leap towards US approval after winning unanimous support from regulatory advisors.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
